Register for OBR daily


GH_edutorial_300x250

To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

AVEO $1.25 0.3010 +31.72%
CVM $1.04 0.0840 +8.79%
PVCT $0.92 0.0410 +4.66%
PBYI $213.01 7.0500 +3.42%
FATE $4.98 0.1300 +2.68%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

CNDO $2.57 -0.2300 -8.21%
ADXS $9.00 -0.7300 -7.50%
BPTH $1.85 -0.1500 -7.50%
OMED $24.98 -1.7800 -6.65%
STML $15.19 -1.0100 -6.23%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | Next > | Last >>

CPRIT Awards Nearly $7 Million to San Antonio Cancer Researchers

(San Antonio Business Journal) Feb 18, 2015 - The Cancer Prevention and Research Institute of Texas (CPRIT) has awarded 58 new grants worth more than $111 million to a number of organizations across the state — including several to the University of Texas Health Science Center at San Antonio.
read article 



Lung Cancer ‘Breathalyser' Goes Into Clinical Trials

(PharmaTimes [UK]) Feb 15, 2015 - A ground-breaking ‘breath test’ for lung cancer is about to go into clinical trials at Glenfield Hospital in Leicester, UK.
read article 



NICE 'Sets Price Too High For NHS Medicines'

(BBC News) Feb 18, 2015 - The price the NHS in England agrees to pay for new medicines is too high, causing more harm than good overall, an analysis suggests.
read article 



Kite Pharma Establishes Manufacturing Capabilities to Support Development and Commercialization of CAR and TCR Cancer Immunotherapy Products

(TheStreet) Feb 19, 2015 - Kite Pharma, Inc., a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT(TM)) products for the treatment of cancer, today announced that it has entered into a lease agreement for a commercial manufacturing facility in El Segundo, California, which is adjacent to Los Angeles International Airport.
read article 



Looking Back on Two Decades of Breast Cancer Treatment: Targeted Therapy and Improved Surgical Procedures are Key Enhancements

(NCCN) Feb 13, 2015 - NCCN has published the 20th annual edition of the NCCN Guidelines® for Breast Cancer, one of the original NCCN Guidelines published in November 1996.
read press release 



Fosko Named Interim Director of SLU Cancer Center

(Saint Louis University) Feb 17, 2015 - Scott W. Fosko, M.D., has been named interim director of Saint Louis University Cancer Center. He will build on the successes of Mark Varvares, M.D., who had been director before recently departing to accept a faculty position at Harvard Medical School.
read press release 



Genmab Enters Commercial DuoBody Technology Agreement With BioNovion in the Field of Immuno-Oncology

(Benzinga) Feb 19, 2015 - Genmab A/S announced today it has entered a co-development and commercialization agreement with BioNovion to evaluate a number of DuoBody product candidates targeting immune checkpoints.
read article 



CMS Oncology Care Model Names NCCN Guidelines as High-Quality Care and Evidence-Based Recommendations

(NCCN) Feb 18, 2015 - Centers for Medicare & Medicaid Services encourages concordance to NCCN Guidelines for Medicare patients in order to achieve better care, smarter spending, and healthier people.
read press release 



Apotex Announces FDA Has Accepted For Filing Its Biosimilar Application For Filgrastim (Grastofil™)

(Apotex) Feb 17, 2015 - Apotex Inc., a rising competitor in the global biosimilars market, announced today that, as of February 13th, 2015, the US Food and Drug Administration has accepted for filing the company's application for Filgrastim [Grastofil™], a biosimilar version of Amgen's Neupogen®. This product has been jointly developed with Intas Pharmaceuticals Ltd.
read corporate press release 



FDA Broadens Revlimid's Approved Use to Include Newly Diagnosed Multiple Myeloma

(The Myeloma Beacon) Feb 18, 2015 - The U.S. Food and Drug Administration (FDA) has ex­panded the of­ficial­ly ap­proved use of Revlimid to include the treat­ment of newly diag­nosed multiple myeloma.
read article 



Merrimack Pharmaceuticals Announces Initiation of a Phase 2 Biomarker-Selected Clinical Trial of MM-121 in Patients With Heregulin Positive Non-Small Cell Lung Cancer

(MarketWatch) Feb 19, 2015 - Merrimack Pharmaceuticals, Inc. today announced the initiation of a global, open-label, biomarker-selected, randomized Phase 2 clinical trial of MM-121, a fully human monoclonal antibody targeting ErbB3, in combination with docetaxel or pemetrexed versus docetaxel or pemetrexed alone in patients with heregulin positive, locally advanced or metastatic non-small cell lung cancer.
read article 



Looking For That Fruit or Vegetable That Might Prevent Cancer?

(Washington Post) Feb 16, 2015 - Only about half of the recommendations on two internationally syndicated TV medical talk shows were supported by scientific evidence, according to a recent study in the journal BMJ.
read article (free registration required) 



Chemical Used to Color Sodas Linked to Cancer Risk

(PBS Newshour/The Rundown blog) Feb 19, 2015 - The brown coloring in your soda may be linked to increased cancer risk, according to a new study.
read article 



New Insight Into a Fragile Protein Linked to Cancer and Autism

(American Chemical Society) Feb 18, 2015 - In recent years, scientists have found a surprising connection between some people with autism and certain cancer patients: They have mutations in the same gene, one that codes for a protein critical for normal cellular health.
read press release 



Biomarker Discovery Offers Clearer Prognosis For Bowel and Rectal Cancer Patients

(Macquarie University [Sydney, Australia]) Feb 19, 2015 - For the first time, a biomarker discovered by Macquarie University and Concord Repatriation General Hospital researchers will allow clinicians to distinguish certain types of colorectal cancer patients who do relatively well after surgery from those who may subsequently die from their disease.
read press release 



Breast Cancer Spread May Be Tied to Cells That Regulate Blood Flow

(MD Anderson) Feb 19, 2015 - Tumors require blood to emerge and spread. That is why scientists at The University of Texas MD Anderson Cancer Center believe that targeting blood vessel cells known as pericytes may offer a potential new therapeutic approach when combined with vascular growth factors responsible for cell death.
read press release 



Roche Gets FDA Priority Review for Cancer Treatment

(Morningstar/Dow Jones Newswires) Feb 19, 2015 - Roche Holding AG said Thursday one of its skin cancer treatments had been granted a priority review by the U.S. Food and Drug Administration, cutting the time the drug might take to become available to patients.
read article 



Breast Cancer Cocktail Buys More Than a Year of Life

(NBCNews.com) Feb 19, 2015 – A cocktail of three breast cancer drugs buys patients an extra 16 months of life — a good news story so unusual, doctors have rushed to make it standard therapy, researchers said Wednesday.
read article 



Vaccine That Targets 9 Strains of HPV Boosts Cancer Protection, Study Says

(Los Angeles Times/Science Now) Feb 18, 2015 - When it comes to HPV vaccines, more protection is better.
read article (free registration required) 



Doctors Strive to Do Less Harm by Inattentive Care

(New York Times) Feb 17, 2015 - Inattentive medical care is now seen as a real harm. To remedy the situation, many hospitals and doctors are surveying those in their care.
read article 



After Lobbying Push, Drugmaker Resubmits Women's Sex Pill

(FoxNews.com/Associated Press) Feb 17, 2015 - The makers of a twice-rejected pill designed to boost female libido are resubmitting their drug to federal health regulators, following a recent lobbying blitz by politicians, women's groups and consumer advocates aimed at pushing it onto the market.
read article 



FDA to Hold a Hearing on Allowing Generic Drug Makers to Update Labels

(Wall Street Journal/Pharmalot blog) Feb 18, 2015 - A rule that the FDA has proposed to update generic drug labeling will be debated at a full-day hearing next month, underscoring the extent to which the proposal has become controversial.
read article (paid subscription required) 



NHS Misses Urgent Cancer Therapy Targets for Whole Year

(BBC News) Feb 18, 2015 - The NHS in England has missed a key cancer target for the whole of 2014, official figures show. At least 85% of patients should start treatment within 62 days of being referred by GPs.
read article 



A Cancer Cluster Is Tough to Prove

(New York Times) Feb 16, 2015 - Last month, thousands of Marines and their families were blocked in federal court from pursuing their claim that the government had given them cancer.
read article 



Cancer Documentary Project Draws Widespread Support

(Medpage Today) Feb 17, 2015 - Three-part "Cancer: Emperor of All Maladies" documentary to debut in late March.
read article (free registration required)